Advancements in Treating Atrial Fibrillation

It may be advantageous to transfer recent-onset atrial fibrillation patients from their regimen of Ibutilide (Corvert) to Vernakalant (Brinavess), a drug quickly earning the respect of physicians because of its ability to rapidly control heart rate. A study conducted by the Medical University of Vienna/General Hospital revealed Vernakalant quickly regulated heart rhythm with fewer side effects than Ibutilie. Because atrial fibrillation is the most common type of cardiac arrhythmia, the medical connotations of this treatment could be far reaching, especially considering its effects: two percent of the population has been diagnosed with atrial fibrillation, and the percentage climbs when factoring in age.

Being able to treat this arrhythmia before it causes a serious financial strain can save patients and healthcare millions of dollars annually. For patients who may be suffering from atrial fibrillation, a remote cardiac monitor from ReactDx could determine an inconsistent rhythm, and if the arrhythmia is detected, Vernakalant may be the next step.

The randomized trial showed several significant advantages, including these highlighted below.

  • A normal sinus rhythm was achieved within approximately ten minutes with Vernakalant; those patients were given Ibutilide averaged 26 minutes before normal sinus rhythm returned.
  • After 90 minutes of treatment, almost 70% of Vernakalant-treated patients experienced sinus rhythm compared to only 43% of Ibutilide-treated patients.
  • Decreased time between treatment and a return to normal sinus rhythm equated to fewer instances of electrical cardioversion under anesthesia to stimulate the heart.
  • Patients who needed electrical cardioversion while taking Vernakalant required fewer shocks for restoration of sinus rhythm.

While Vernakalant was the drug of choice for patients with zero to moderate structural heart disease and who had suffered from recent-onset atrial fibrillation, Ibutilide was still preferred for those experiencing atrial flutter. Keep apprised of the latest in cardiovascular information by reading our blogs, and contact ReactDx at (800) 23-HEART (234-3278) to speak with one of our representatives concerning the most technologically advanced remote cardiac monitors on the market.

Jodi is a seasoned Human Resources professional who thrives on change and transformation. She fell in love with Human Resources when she attended Penn State University for graduate school in Public Administration with a curriculum that emphasized Human Resources. After earning her Master’s degree she began her career in the manufacturing industry in Talent Acquisition and was eventually assigned the overall HR Management responsibility of three divisions which included collective bargaining. Ultimately, she made her way to transitioning a new division of a Fortune 100 company under the corporate model as well as developing and executing Human Resources policies and procedures across a broad range of functional disciplines. At the next juncture of her career, she was tapped on the shoulder by former Executives that she previously worked with to join in on an exciting start-up. Today, Jodi is the Vice President of Talent Relations and Development for Medicomp Inc dba ReactDx and is responsible for managing the strategic Human Resources function which includes mergers and acquisitions for this rapidly expanding company.

Jodi and her husband enjoy landscaping, finding new restaurants and traveling whenever life gives them the opportunity.

    *This form is intended for sales inquiries/information only. Do not include any patient health information (PHI) with your submission.

    On: all lights. Off: no light. Monitoring - Good: green light. Symptom press: green light, sound. Check Pendant: blue light. Check Battery: red light, sound.
    Do: wear always, fully insert in cradle, turn off to charge, dry, key near handset, return promptly. Don't: discard pendant, submerge, move patch